Apogee Therapeutics is committed to maintaining your privacy and recognizes the importance of providing protection for any personal data that you choose to share with us or that we maintain about you.

Apogee Therapeutics, Inc.

Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. 

Venrock Healthcare Capital Partners

Wellington Management

OrbiMed

Perceptive Advisors

RA Capital Management

RTW Investments

Deep Track Capital

Fairmount Funds Management

Fidelity

Fidelity Management and Research Company

Apogee Therapeutics

We are excited to share that Apogee CMO Carl Dambkowski has been named to this year's In Vivo Rising Leaders list, honoring entrepreneurs and innovators who represent the next wave of creativity in #healthcare. We are grateful to have leaders like Carl paving the way for our innovations in I&I therapies to make an impact and never stopping at “good enough.” Congratulations, Carl!

We are thrilled to announce the first healthy volunteer participants have been dosed in the Phase 1 clinical trial of APG808, our novel half-life extended IL-4Rα antibody for the treatment of #COPD and other inflammatory diseases. We expect to report interim subcutaneous safety and pharmacokinetic data in the second half of this year. CEO Michael Henderson shares more below. https://lnkd.in/e3tQyXmD

A big thank you to Nasdaq for joining us to celebrate the closing of our upsized $483M follow-on financing, extending our cash runway into Q1 2028. At Apogee, we are dedicated to advancing our programs to transform the I&I space for patients with high unmet needs and refuse to stop at “good enough.”

We are pleased to announce the closing of our upsized $483M public offering, extending our cash runway into Q1 2028. Full details below. https://lnkd.in/eAF-FTmj

We recently reported pipeline progress and fourth quarter and full year 2023 financial results. This includes the positive interim results from our APG777 Phase 1 study as well as an update on the Phase 1 clinical study of APG808, a potentially best-in-class antibody for chronic obstructive pulmonary disease (#COPD) and asthma, which is set to start ahead of schedule in the first half of this year. Read more below. https://lnkd.in/eNKSCK8m

Today we announced positive Phase 1 interim data from the first-in-human study of our lead program, APG777. Initial data show APG777 was well tolerated in healthy volunteers and initial PK data support potential best-in-class dosing of every 3 or 6 months. Based on these findings, we plan to accelerate our timelines again and initiate a Phase 2 clinical trial of APG777 in moderate-to-severe #atopicdermatitis in the first half of this year. Read more below. https://lnkd.in/eZrX_Uzh

msh id	COM:APOGEETHERAPEUTICS
symbol	-
name	Apogee Therapeutics, Inc.
homepage url	https://apogeetherapeutics.com
country	US
sector	9
industry	Healthcare & Health Services
market	PRIVATE
employee count	105
crunchbase url	https://www.crunchbase.com/organization/apogee-therapeutics
linkedin url	https://www.linkedin.com/company/apogee-therapeutics
founders	-

market cap	1.11B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	13.96
growth score 28	19.98
growth score 90	46.86
growth score 365	43.93

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:APOGEETHERAPEUTICS

Apogee Therapeutics, Inc.

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-